417 related articles for article (PubMed ID: 31110158)
1. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
Shafran JS; Andrieu GP; Györffy B; Denis GV
Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
[TBL] [Abstract][Full Text] [Related]
2. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
[TBL] [Abstract][Full Text] [Related]
3. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y
Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037
[TBL] [Abstract][Full Text] [Related]
4. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
5. SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.
Martinez RS; Salji MJ; Rushworth L; Ntala C; Rodriguez Blanco G; Hedley A; Clark W; Peixoto P; Hervouet E; Renaude E; Kung SHY; Galbraith LCA; Nixon C; Lilla S; MacKay GM; Fazli L; Gaughan L; Sumpton D; Gleave ME; Zanivan S; Blomme A; Leung HY
Cancer Res; 2021 Jul; 81(13):3664-3678. PubMed ID: 33985973
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
7. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
[No Abstract] [Full Text] [Related]
8. Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality.
Xu Y; Wang Q; Xiao K; Liu Z; Zhao L; Song X; Hu X; Feng Z; Gao T; Zuo W; Zeng J; Wang N; Yu L
Mol Cancer Ther; 2020 Jun; 19(6):1221-1231. PubMed ID: 32220972
[TBL] [Abstract][Full Text] [Related]
9. Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer.
Yamamoto S; Takayama KI; Obinata D; Fujiwara K; Ashikari D; Takahashi S; Inoue S
Cancer Sci; 2019 Nov; 110(11):3476-3485. PubMed ID: 31454442
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract][Full Text] [Related]
12. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
13. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
[TBL] [Abstract][Full Text] [Related]
15. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
16. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
[TBL] [Abstract][Full Text] [Related]
17. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.
Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY
Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098
[TBL] [Abstract][Full Text] [Related]
18. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
19. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
Zhou L; Zhang C; Yang X; Liu L; Hu J; Hou Y; Tao H; Sugimura H; Chen Z; Wang L; Chen K
Clin Transl Med; 2021 Jun; 11(6):e449. PubMed ID: 34185414
[TBL] [Abstract][Full Text] [Related]
20. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
